10-Q: Merus N.V. Accelerates Pipeline, Extends Cash Runway

Merus N.V. reports increased net losses driven by accelerated R&D for its oncology pipeline, while significantly bolstering its cash reserves to fund operations into 2028.

Summary

• Net loss for the six months ended June 30, 2025, significantly increased to $254.7 million, compared to $84.5 million for the same period in 2024.
• Total revenue for the six months ended June 30, 2025, rose to $35.3 million, up from $15.2 million in 2024, primarily due to $13.3 million in commercial material revenue from BIZENGRI sales by Partner Therapeutics (PTx) and increased collaboration revenue.
• Research and development expenses surged to $174.0 million for the six months ended June 30, 2025, an $86.3 million increase from $87.7 million in 2024, largely driven by petosemtamab clinical trials.
• General and administrative expenses increased to $47.4 million for the six months ended June 30, 2025, up $8.7 million from $38.7 million in 2024.
• A substantial foreign exchange loss of $76.2 million was recorded for the six months ended June 30, 2025, compared to a gain of $18.1 million in the prior year period.
• Cash, cash equivalents, and marketable securities totaled $892.0 million as of June 30, 2025, providing a projected funding runway at least into 2028.
• Successfully completed a public offering on June 5, 2025, raising approximately $326.0 million in net proceeds.
• Petosemtamab (MCLA-158) Phase 3 registrational trials (LiGeR-HN1 and LiGeR-HN2) in HNSCC are enrolling, with substantial enrollment expected by year-end 2025 and potential top-line interim data in 2026.
• Updated Phase 2 data for petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC showed a 63% confirmed overall response rate (27/43 evaluable patients) and a 79% overall survival rate at 12 months.
• Initial clinical data for petosemtamab in metastatic colorectal cancer (mCRC) is planned for the second half of 2025.
• BIZENGRI (zenocutuzumab-zbco) received FDA accelerated approval for advanced, unresectable or metastatic NRG1 gene fusion positive pancreatic adenocarcinoma or NSCLC, and is exclusively licensed to PTx for U.S. commercialization.
• Entered a research collaboration and license agreement with Biohaven Ltd. to co-develop three novel bispecific antibody drug conjugates (ADCs), receiving a $5.0 million upfront payment in Biohaven shares.

Sentiment

Score: 7

Explanation: While net losses increased significantly, this is largely attributable to accelerated R&D for a promising pipeline and a non-operational foreign exchange loss. The substantial capital raise and extended cash runway into 2028 provide strong financial stability for continued clinical development. The FDA accelerated approval for BIZENGRI and positive interim data for petosemtamab are key operational successes, indicating good progress on strategic objectives despite the increased burn.

Positives

• Cash, cash equivalents, and marketable securities increased to $892.0 million as of June 30, 2025, extending the funding runway at least into 2028.
• Successfully raised approximately $326.0 million in net proceeds from a public offering in June 2025.
• Total revenue increased significantly by $20.1 million for the six months ended June 30, 2025, driven by new commercial material revenue and collaboration revenue.
• BIZENGRI (zenocutuzumab-zbco) received FDA accelerated approval, marking a significant regulatory milestone and generating commercial material revenue through the PTx license.
• Petosemtamab (MCLA-158) Phase 3 registrational trials are actively enrolling, with potential top-line interim data expected in 2026.
• Positive interim clinical data for petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC, showing a 63% ORR and 79% 12-month OS rate.
• Received Breakthrough Therapy Designations (BTD) for petosemtamab in both monotherapy and combination settings for HNSCC, potentially expediting development.
• New collaboration with Biohaven Ltd. for bispecific ADCs, including a $5.0 million upfront payment.

Negatives

• Net loss for the six months ended June 30, 2025, increased substantially to $254.7 million, up from $84.5 million in the prior year period.
• Operating expenses increased by $95.0 million for the six months ended June 30, 2025, primarily due to higher research and development costs.
• Experienced a significant foreign exchange loss of $76.2 million for the six months ended June 30, 2025, compared to a gain in the prior year.
• Accumulated deficit reached $1,223.1 million as of June 30, 2025, indicating continued unprofitability since inception.
• Cash used in operating activities increased by $126.9 million for the six months ended June 30, 2025, reflecting higher cash burn.

Risks

• Incurred significant net losses since inception and expect to continue incurring significant expenses and operating losses for the foreseeable future, potentially never achieving or maintaining profitability.
• Require substantial additional capital to finance operations; inability to raise capital when needed or on acceptable terms may force delays, reductions, or elimination of research and drug development programs or future commercialization efforts.
• Limited operating history and experience with registrational clinical trials, making it difficult to evaluate current business and predict future success.
• Outcome of pre-clinical testing and early clinical trials may not be predictive of success in later clinical trials, and results may not satisfy regulatory requirements.
• Clinical trial and regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, potentially leading to additional costs or delays.
• Antibody candidates may have serious adverse, undesirable, or unacceptable side effects, alone or in combinations, which could delay or prevent marketing approval or limit commercial profiles.
• Never commercialized an antibody candidate independently and may lack necessary expertise, personnel, and resources to successfully commercialize products on its own or with licensees.
• May not be able to successfully manufacture product candidates in sufficient quality and quantity, delaying or preventing development and commercialization.
• Reliance on third parties (clinical investigators, CROs, CMOs) to conduct studies and trials; failure to perform contractual duties or meet deadlines could substantially harm the business.
• Due to limited resources, must prioritize development of certain antibody candidates, and these decisions may prove wrong and adversely affect revenues.
• Intense competition for qualified personnel in the industry; inability to retain or hire key personnel may hinder business growth.
• Operates in highly competitive and rapidly changing industries; competitors developing more effective, safer, or less expensive products could negatively impact commercial opportunities.
• Success depends on ability to protect intellectual property; failure to adequately protect or maintain patents, or if others do not respect IP rights, could lead to direct competition.
• Existing and potential future collaboration and license agreements are important; inability to maintain or execute new arrangements, or if arrangements are unsuccessful, could adversely affect the business.
• Trading prices for common shares have been highly volatile due to global economic conditions and geopolitical instability, potentially impacting ability to raise capital.
• Accelerated approval for BIZENGRI is contingent upon verification of clinical benefit in confirmatory trials; failure to do so could lead to withdrawal of approval.
• Biclonics, Triclonics, and ADClonics technology platforms are unproven for additional therapeutic approvals beyond BIZENGRI.
• Reliance on third parties for biological materials, linker, and payload technologies, which may not meet expectations or requirements.
• Failure to successfully validate, develop, and obtain regulatory approval or certification for companion diagnostics could harm development strategy.
• Future sales, or the possibility of future sales, of a substantial number of common shares could adversely affect the share price due to dilution.
• Provisions in articles of association or Dutch corporate law might deter acquisition bids or prevent attempts to replace board members.
• May be classified as a passive foreign investment company (PFIC) for U.S. federal income tax purposes, resulting in adverse tax consequences for U.S. investors.
• Subject to economic, political, regulatory, and other risks associated with international operations, including foreign currency exchange rate fluctuations.
• Risks from improper conduct by employees, agents, contractors, or collaborators, including noncompliance with applicable laws and regulations, could adversely affect reputation and business.
• Potential exposure to costly and damaging product liability claims and reputational risks, which may not be fully covered by insurance.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable; failure to obtain approval would substantially harm the business.
• Ongoing obligations and continued regulatory review for approved products may result in significant additional expense and potential market withdrawal if problems arise.
• Dependence on patient enrollment in clinical trials; inability to enroll patients in a timely manner could adversely affect research and development efforts.
• Successful commercialization depends on adequate coverage, reimbursement levels, and pricing policies by governmental authorities and health insurers; failure to obtain or maintain could limit marketability.
• Limited marketing, sales, or distribution infrastructure; inability to develop or outsource these capabilities could hinder commercialization.
• Antibody candidates intended as biologic products may face biosimilar competition sooner than anticipated, reducing market exclusivity.
• Subject to environmental, health, and safety laws and regulations, potentially leading to liability and substantial expenses.
• Information technology systems, or those of CROs/contractors, may fail or suffer security breaches, adversely affecting business operations and data integrity.
• Future growth and ability to compete depend on retaining key personnel and recruiting additional qualified personnel; management transitions pose risks.
• Business interruptions from natural disasters, public health crises, or geopolitical actions could adversely affect operations.
• Do not expect to pay cash dividends for the foreseeable future; returns on investment will depend on share price appreciation.
• If securities or industry analysts publish inaccurate or unfavorable research, the price of common shares and trading volume could decline.
• Incur increased costs as a public company, requiring substantial management time for compliance initiatives and corporate governance practices.
• Varied and differing positions on environmental sustainability and social initiatives by stakeholders could increase costs, harm reputation, and adversely impact financial results.

Future Outlook

Existing cash, cash equivalents, and marketable securities of $892.0 million as of June 30, 2025, are expected to fund operations at least into 2028. The company anticipates continued significant expenses and operating losses as antibody candidates advance through development and commercialization. Initial clinical data for petosemtamab in mCRC is planned for the second half of 2025, and Phase 3 trials for petosemtamab in HNSCC are expected to be substantially enrolled by year-end 2025, with potential top-line interim readouts in 2026.

Management Comments

• We expect to continue to incur significant expenses and operating losses for the foreseeable future as our antibody candidates advance through discovery, pre-clinical development and clinical trials and as we seek regulatory approval and pursue commercialization of any approved antibody candidate.
• Based on our current operating plan, we expect that our existing cash, cash equivalents and marketable securities of $892.0 million as of June 30, 2025 will fund our operations at least into 2028.
• We have based this estimate on assumptions that may prove to be wrong, particularly as the process of producing and testing product candidates in clinical trials is costly and the timing of progress in these trials is uncertain. As a result, we could use our capital resources sooner than we expect.
• We remain interested in exploring partnering MCLA-129 to sufficiently resource the development of MCLA-129 and the potential benefit it may have for patients.

Industry Context

The biopharmaceutical industry is highly competitive and rapidly evolving, with significant R&D investments required for drug development. Merus N.V. operates in the oncology space, focusing on innovative antibody therapeutics, including bispecific and trispecific antibodies and ADCs. The company's strategy aligns with industry trends of developing targeted therapies and leveraging platform technologies. The regulatory landscape, particularly in the EU, is undergoing significant review, which could impact future development and commercialization. Global economic volatility, including inflation and interest rates, and geopolitical conflicts continue to pose challenges for capital raising and operational stability across the industry.

Comparison to Industry Standards

• NA The filing does not provide specific comparable company or project data to assess results against global benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• Filed a complaint in the United States District Court of Delaware against Xencor, Inc. on August 5, 2024, alleging infringement of U.S. Patent Nos. 9,944,965, 9,358,268, and 11,926,859, seeking damages, equitable remedies, and attorneys' fees. Xencor filed a motion to dismiss on October 10, 2024.
• Xencor filed two petitions for inter partes review (IPR) before the Patent Technical Appeal Board (PTAB) on February 11, 2025, challenging the validity of U.S. Patent Nos. 9,358,268 and 11,926,859. Merus's requests for discretionary denial were denied by the USPTO Acting Director on July 17, 2025, referring the petitions to PTAB for a decision on institution.
• Kymab Limited filed a notice of opposition against Merus's EP3456190 patent in the European Opposition Division of the European Patent Office on August 19, 2022. The European Opposition Division maintained the patent as granted on February 16, 2024. Kymab filed a notice of appeal in April 2024, with oral proceedings scheduled for July 9, 2026.

Related Party Transactions

• Gilead Sciences, Inc. purchased 452,527 common shares for $25.0 million as part of the collaboration agreement in March 2024.
• Biohaven Ltd. provided a $5.0 million upfront payment in the form of Biohaven shares as part of the research collaboration and license agreement in January 2025.

Stakeholder Impact

• Shareholders: Potential dilution from future equity financings, but also benefit from extended cash runway and pipeline progression. Share price volatility remains a risk.
• Employees: Competition for qualified personnel is intense, but new hires in key roles (Chief Medical Officer, Chief People Officer) indicate continued investment in human capital. Share-based compensation is a significant expense.
• Customers/Patients: Continued development of innovative oncology therapeutics aims to provide new treatment options, including the FDA-approved BIZENGRI for NRG1+ cancers.
• Collaborators/Licensees: Ongoing collaborations (Gilead, PTx, Biohaven, Lilly, Incyte, Ono) are crucial for funding and development, but performance and potential termination risks exist.
• Creditors: No outstanding debt, reducing immediate risk, but future debt financing could involve restrictive covenants.

Next Steps

• Substantial enrollment of petosemtamab Phase 3 trials (LiGeR-HN1 and LiGeR-HN2) by year-end 2025.
• Potential top-line interim readout for one or both petosemtamab Phase 3 trials in 2026.
• Provide initial clinical data for petosemtamab in metastatic colorectal cancer (mCRC) in the second half of 2025.
• Continue ongoing translational work on potential biomarkers for zenocutuzumab outside of NRG1+ cancer.
• Continue investigation of MCLA-129 in MET ex14 NSCLC expansion cohort and in combination with chemotherapy in 2L+ EGFRm NSCLC.
• Explore partnering MCLA-129 to sufficiently resource its development.
• Continue research and development of other pre-clinical antibody candidates.
• Conduct additional confirmatory studies for BIZENGRI to verify clinical benefit for full FDA approval.

Key Dates

Recommendation

Merus N.V. demonstrates strong operational execution with significant advancements in its clinical pipeline, particularly with petosemtamab's Phase 3 progression and positive interim data, and the FDA accelerated approval of BIZENGRI. While net losses have increased, this is a direct consequence of accelerated R&D investment, which is critical for a biotech at this stage. The substantial cash reserves of $892.0 million, bolstered by a recent $326.0 million capital raise, provide a robust funding runway into 2028, significantly de-risking near-term liquidity concerns. The company's innovative Biclonics and Triclonics platforms, coupled with strategic collaborations, position it for long-term growth. Despite ongoing legal proceedings and inherent biotech risks, the clinical progress and financial stability make it an attractive long-term investment for investors with a higher risk tolerance.

Keywords

Oncology, Biotechnology, Antibody Therapeutics, Bispecific Antibodies, Trispecific Antibodies, ADCs, Clinical Trials, Drug Development, FDA Approval, NRG1 Fusion Cancer, HNSCC, Colorectal Cancer, NSCLC, Petosemtamab, Zenocutuzumab, MCLA-129, MCLA-145, Biologics, SEC Filing, Financial Results, Cash Runway, Capital Raise, Collaborations, Intellectual Property, Risk Factors